BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a commercial-stage, multi-product biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with genetic diseases. The company operates a decentralized hub-and-spoke model designed to maximize the probability of success by maintaining… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BridgeBio Pharma, Inc. does
In the company’s own words
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a commercial-stage, multi-product biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with genetic diseases. The company operates a decentralized hub-and-spoke model designed to maximize the probability of success by maintaining lean, asset-focused teams supported by centralized business operations, clinical expertise, and commercial infrastructure. This structure enables BridgeBio to advance multiple programs concurrently while maintaining capital discipline and flexibility to allocate resources based on emerging clinical data.
The company's commercial portfolio includes Attruby (acoramidis), a next-generation oral small molecule transthyretin stabilizer approved by the FDA in November 2024 for treating transthyretin amyloid cardiomyopathy in adults. Attruby generated $362.4 million in U.S. net product revenues in 2025 and has achieved significant market penetration with over 7,800 unique patient prescriptions and more than 1,850 prescribing healthcare professionals. Outside the United States, acoramidis is marketed as Beyonttra through strategic partnerships with Bayer in Europe and Alexion in Japan, contributing $105.0 million in license and services revenue in 2025.
BridgeBio's advanced pipeline includes multiple Phase 3 programs with positive clinical data, including low-dose infigratinib for achondroplasia, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and encaleret for autosomal dominant hypocalcemia type 1. The company also maintains approved products including Nulibry for molybdenum cofactor deficiency and previously commercialized Truseltiq for cholangiocarcinoma.
Since its founding ten years ago, BridgeBio has generated 19 investigational new drug applications and contributed to over 70 peer-reviewed scientific publications. The company has treated more than 8,500 patients with its approved medicines and maintains minority equity interests in GondolaBio and BridgeBio Oncology Therapeutics. BridgeBio does not own manufacturing facilities and relies entirely on third-party contract manufacturing organizations for drug substance and product production. More information is available at www.bridgebio.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 1743881
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BridgeBio Pharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in BridgeBio Pharma, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · BridgeBio Pharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
BridgeBio Pharma, Inc.’s bonds, as funds hold them
Funds report holding 4 issues of BridgeBio Pharma, Inc.’s debt, $502.47M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.72%, maturing 2027 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BridgeBio Pharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BridgeBio Pharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BridgeBio Pharma, Inc.'s last four quarterly filings that the numbers alone won't show?”